Market Place
Sourcing Support
AstraZeneca Cuts Asthma and Rare Disease Units; Boosts Cancer
30 Apr 2026 //
BIOSPACE
Astra eyes 5th Ultomiris indication after kidney disease trial
22 Apr 2026 //
PRESS RELEASE
AstraZeneca’s Strensiq successor misses ph. 3 rare disease goal
31 Mar 2026 //
FIERCE BIOTECH
CDT Advances Out-Licensing With Sarborg Signature Analysis
23 Mar 2026 //
GLOBENEWSWIRE
Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins
07 Nov 2025 //
BUSINESSWIRE
Takeda Drops Az-Partnered Neurological Program After Ph. 2 Fail
30 Oct 2025 //
FIERCE BIOTECH
Novartis Sues Az`s Alexion Over `Misleading` Ultomiris Marketing
22 Oct 2025 //
FIERCE PHARMA
JCR Pharma & Alexion Hit Milestone in Neurodegenerative Program
19 Sep 2025 //
PHARMAWEB
AstraZeneca India Introduces Eculizumab for aHUS, PNH Treatment
09 Sep 2025 //
EXPRESS PHARMA
AZ`s Alexion Highlights gMG in Upcoming Awareness Film
31 Jul 2025 //
FIERCE PHARMA
AstraZeneca`s Rare Immune Disorder Drug Succeeds in Trial
25 Jul 2025 //
REUTERS
Global Coalition Starts AZD1390 in GBM AGILE Trial
13 May 2025 //
PR NEWSWIRE
AstraZeneca`s $800M rare disease bet hits primary Ph 3 goal
17 Mar 2025 //
FIERCE BIOTECH
Merck, AstraZeneca Announce Phase 3 Win for Cancer Drug
12 Nov 2024 //
FIERCE BIOTECH
AZ licenses discarded rare disease drug to Monopar Therapeutics
25 Oct 2024 //
FIERCE BIOTECH
AstraZeneca`s Fasenra Approved in the US for Rare Blood Vessel Disease
19 Sep 2024 //
CONTRACTPHARMA
Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis
25 Jul 2024 //
FIERCE PHARMA
Rare Disease Centre of Excellence to open in Emirate in collabn with AstraZeneca
07 Jun 2024 //
BIOSPECTRUM ASIA
US FDA approves Amgen`s biosimilar to AZ`s rare blood disorder treatment
29 May 2024 //
REUTERS
SEC recommends import, marketing permission for AstraZeneca`s rare disease drug
30 Apr 2024 //
PHARMABIZ
Lights, camera and community: AZ’s Alexion creates an original film
11 Apr 2024 //
FIERCE BIOTECH
AZ India appoints Vinay Sharma as Business Unit Head - Rare Disease
26 Mar 2024 //
INDINPHARMAPOST
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo
19 Mar 2024 //
BUSINESSWIRE
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
15 Mar 2024 //
REUTERS
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
22 Dec 2023 //
PRESS RELEASE
AstraZeneca to buy Pfizer`s rare disease gene therapy portfolio for up to $1 bln
28 Jul 2023 //
PRESS RELEASE
AZ showcases advances across rare and malignant haematological conditions
17 May 2023 //
PHARMABIZ
AstraZeneca dumps $855M, near-approval rare disease drug
28 Apr 2023 //
FIERCE BIOTECH
Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs
25 Apr 2023 //
BIOPHARMADIVE
AstraZeneca grows Canadian snowshoe print with 500 new jobs and rare disease hub
28 Feb 2023 //
FIERCE BIOTECH
Alexion, AZ Rare Disease, Completes Acquisition of LogicBio Therapeutics
16 Nov 2022 //
BUSINESSWIRE
AZ expands global footprint in rare disease with availability of first Alexion
11 Nov 2022 //
PRESS RELEASE
AZ to present over 60 abstracts across its industry-leading CVRM portfolio
31 Oct 2022 //
PHARMABIZ
Alexion, AstraZeneca Rare Disease to Acquire LogicBio
04 Oct 2022 //
PRNEWSWIRE
AZ`s struggling cancer drug nabs priority review in rare disease
15 Nov 2019 //
FIERCE PHARMA
$250M AZ spinoff preps leap into 3-way battle with titans for raredisease market
07 May 2019 //
ENDPTS
With positive phase 2, Neurocrine eyes trial for CAH drug
12 Mar 2019 //
FIERCE BIOTECH
Fasenra granted Orphan Drug Designation by FDA
07 Feb 2019 //
PHARMA TIMES
AstraZeneca digs deeper into cancer with Innate stake
23 Oct 2018 //
REUTERS
Roche puts down $75M to sign on AMD drug, following Huntington’s deal
11 Oct 2018 //
ENDPTS
AstraZeneca nabs FDA nod for rare leukemia drug Lumoxiti
15 Sep 2018 //
FIERCE PHARMA
AbbVie, J&J score early nod for Imbruvica in rare cancer
27 Aug 2018 //
FIERCE PHARMA
Orphan Drug Regulations in Europe
27 Aug 2018 //
RAPS
AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures
26 Jul 2018 //
FIERCE BIOTECH
Could Amgen soften the biosim blow with an Alexion buy?
16 Jul 2018 //
FIERCE PHARMA
CVC revs up rare disease ambitions with $3.5B Recordati buy
05 Jul 2018 //
FIERCE PHARMA
AZ farms out rare disease therapy to Mereo
31 Oct 2017 //
PHARMA TIMES
AstraZeneca gets Rare Pediatric Disease Priority Review Voucher
08 Sep 2015 //
SEEKING ALPHA
